New hope for arthritis patients: experimental drug targets inflammation
NCT ID NCT06276998
First seen Jan 16, 2026 · Last updated May 08, 2026 · Updated 17 times
Summary
This study tests a new drug called LNK01001 (Zemprocitinib) in 430 adults with moderate-to-severe rheumatoid arthritis who did not get enough relief from other treatments. The drug aims to reduce joint pain and swelling by targeting inflammation. Participants will receive either the drug or a placebo for 24 weeks, followed by a longer safety period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.